Riverwater Partners, an investment management company, released its “Sustainable Value Strategy” Q4 2024 investor letter. A ...

Upslope Capital Management, an investment management firm, released its fourth-quarter 2024 investor letter. A copy of the ...

UBS has downgraded Charles River Laboratories (NYSE:CRL) to neutral from buy, citing concerns about decelerating sales growth ...

Fintel reports that on January 22, 2025, William Blair downgraded their outlook for Charles River Laboratories International ...

William Blair downgraded Charles River Laboratories to market perform citing concerns over a decline in early-stage R&D funding from large pharmas. Read more here.

Analysts have recently evaluated Charles River and provided 12-month price targets. The average target is $214.5, accompanied by a high estimate of $250.00 and a low estimate of $185.00. A 2.72% drop ...

This was the stock's third consecutive day of losses.

William Blair downgraded Charles River (CRL) to Market Perform from Outperform without a price target “There is simply too much working ...

UBS Group reaffirmed their neutral rating on shares of Charles River Laboratories International (NYSE:CRL – Free Report) in a research note released on Friday morning, MarketBeat reports. They ...

Equities research analysts at William Blair reduced their FY2025 earnings per share (EPS) estimates for shares of Charles River Laboratories International in a report issued on Wednesday, January 15th ...

This was the stock's fourth consecutive day of losses.

Charles River and Akron Bio have announced the integration of the latter’s CSS liquid cytokines into the former's Cell ...